FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for the treatment of myelodysplastic syndrome (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup. Inhibitors of the CD95 signaling pathway that binds the CD95 receptor (CD95) and/or CD95 ligand (CD95L) is used.
EFFECT: method widens the range of therapeutic agents.
18 cl, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE ERYTHROCYTE COUNT | 2020 |
|
RU2814047C2 |
| MEDICATIONS FOR TREATING PEMPHIGUS CONTAINING ANTIBODIES TO Fas-LIGAND | 2008 |
|
RU2558260C2 |
| PREPARATIONS, CONTAINING ANTIBODIES AGAINST Fas LIGAND, FOR TREATING PEMPHIGUS | 2009 |
|
RU2556818C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| FUNCTIONALIZED ERYTHROID CELLS | 2018 |
|
RU2779315C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS | 2019 |
|
RU2824194C2 |
| METHODS FOR CELL CULTIVATION AND SETS AND DEVICE FOR THEM | 2016 |
|
RU2761557C2 |
